Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Inspection Fees Face Tough Road In Congress As PhRMA Remains Opposed

Executive Summary

At user fee hearing, PhRMA’s Wheadon counters questions from Rep. Dingell, saying FDA already is receiving resources to conduct GMP inspections outside the U.S.


Related Content

FDA User Fee Bill Up For Final Senate Action After House Passage
Tropical Disease Development Partnerships Want More Help From FDA
GOP Drug Shortage Strategy Pushes FDA Reform, Reimbursement Over Notification
Supply Chain Security Issues To Emerge During Subcommittee Hearing On PDUFA
Track and Trace Standards Coming Shortly, FDA Says
Generic Facility Fee Unlikely To Be Charged Until A Few Months After GDUFA Implementation
FDA Envisions Many Regulatory Coalitions Dealing With Globalization Issues
FDA Wants Authority To Enforce Track-And-Trace System For Drugs
Inspection Fees For Drug, Ingredient Manufacturers Could End Up In PDUFA, Sen. Harkin Says
Is Silence Golden For Brand Companies On Inspection Fees?


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts